• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

化疗引起的周围神经病变自我检查表的有效性

Validity of the chemotherapy-induced peripheral neuropathy self-check sheet.

作者信息

Miyoshi Yumiko, Onishi Chie, Fujie Mifumi, Senoo Naomi, Wakatsuki Ritsuko, Suzumiya Junji

机构信息

Department of Nursing, Shimane University Hospital, Japan.

出版信息

Intern Med. 2015;54(7):737-42. doi: 10.2169/internalmedicine.54.3318. Epub 2015 Apr 1.

DOI:10.2169/internalmedicine.54.3318
PMID:25832934
Abstract

Objective Chemotherapy-induced peripheral neuropathy (CIPN) is a major dose-limiting side effect of some anti-cancer drugs. However, medical staff frequently encounter difficulties in ascertaining the severity of CIPN. We sought to develop a questionnaire in order to accurately assess CIPN. The validity of this questionnaire was compared with that of free-style interviews. Methods We developed the CIPN self-check sheet by analyzing existing self-assessment tools for CIPN and matching the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) grades. From August to December 2011, 77 cancer patients participated in this study. In order to evaluate the validity of the CIPN self-check sheet compared with a free-style interview assessment, the cross-classification and κ coefficients between the CTCAE grades from each assessment and those from a comprehensive assessment were analyzed. The comprehensive assessment utilized information obtained from the medical examination, free-style interview and CIPN self-check sheet. Results Upon completion of the study, 248 CIPN self-check sheets were collected (median number of sheets per patient, 3; range, 1-14). The cross-classification analysis illustrated that the CIPN self-check sheet successfully identified all grade 3 cases. The coefficient of the CIPN self-check sheet was significantly higher than that of the free-style interviews [κ values: 0.988 (p<0.01) and 0.501 (p<0.01) for the self-check sheet and interviews, respectively]. Conclusion The CIPN self-check sheet can be used to assess the severity of CIPN based on the CTCAE grade more accurately than free-style interviews.

摘要

目的 化疗引起的周围神经病变(CIPN)是某些抗癌药物的主要剂量限制性副作用。然而,医务人员在确定CIPN的严重程度时经常遇到困难。我们试图开发一份问卷以准确评估CIPN。将该问卷的有效性与自由式访谈的有效性进行比较。方法 通过分析现有的CIPN自我评估工具并与美国国立癌症研究所不良事件通用术语标准(NCI-CTCAE)分级相匹配,我们开发了CIPN自我检查表。2011年8月至12月,77名癌症患者参与了本研究。为了评估CIPN自我检查表与自由式访谈评估相比的有效性,分析了每次评估的CTCAE分级与综合评估的CTCAE分级之间的交叉分类和κ系数。综合评估利用了从体格检查、自由式访谈和CIPN自我检查表中获得的信息。结果 研究结束时,共收集到248份CIPN自我检查表(每位患者的检查表中位数为3份;范围为1 - 14份)。交叉分类分析表明,CIPN自我检查表成功识别了所有3级病例。CIPN自我检查表的系数显著高于自由式访谈的系数[自我检查表和访谈的κ值分别为0.988(p<0.01)和0.501(p<0.01)]。结论 与自由式访谈相比,CIPN自我检查表可更准确地根据CTCAE分级评估CIPN的严重程度。

相似文献

1
Validity of the chemotherapy-induced peripheral neuropathy self-check sheet.化疗引起的周围神经病变自我检查表的有效性
Intern Med. 2015;54(7):737-42. doi: 10.2169/internalmedicine.54.3318. Epub 2015 Apr 1.
2
Chemotherapy-induced peripheral neuropathy-patient-reported outcomes compared with NCI-CTCAE grade.化疗诱导性周围神经病-患者报告结局与 NCI-CTCAE 分级比较。
Support Care Cancer. 2019 Dec;27(12):4771-4777. doi: 10.1007/s00520-019-04781-6. Epub 2019 Apr 10.
3
Optimizing Clinical Screening for Chemotherapy-Induced Peripheral Neuropathy.优化化疗诱导周围神经病变的临床筛查。
J Pain Symptom Manage. 2019 Dec;58(6):1023-1032. doi: 10.1016/j.jpainsymman.2019.07.021. Epub 2019 Jul 30.
4
Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice.多发性骨髓瘤化疗所致神经病变:对生活质量的影响以及一份用于日常临床实践中制定常见毒性标准分级的问卷的编制
Support Care Cancer. 2016 Jun;24(6):2411-20. doi: 10.1007/s00520-015-3032-y. Epub 2015 Dec 3.
5
Development and validation of the comprehensive assessment scale for chemotherapy-induced peripheral neuropathy in survivors of cancer.癌症幸存者化疗诱导周围神经病变综合评估量表的制定与验证。
BMC Cancer. 2019 Sep 10;19(1):904. doi: 10.1186/s12885-019-6113-3.
6
[Chemotherapy-induced peripheral neuropathy; impact on quality of life].[化疗引起的周围神经病变;对生活质量的影响]
Ned Tijdschr Geneeskd. 2014;158:A7455.
7
Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS).基于 Rasch 模型构建的化疗诱导周围神经病患者总体残疾量表(CIPN-R-ODS)。
Eur J Cancer. 2013 Sep;49(13):2910-8. doi: 10.1016/j.ejca.2013.04.004. Epub 2013 May 10.
8
Reference data of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 Questionnaire in the general Dutch population.欧洲癌症研究与治疗组织(EORTC)QLQ-CIPN20问卷在荷兰普通人群中的参考数据。
Eur J Cancer. 2016 Dec;69:28-38. doi: 10.1016/j.ejca.2016.09.020. Epub 2016 Nov 1.
9
Validity of Patient-Reported Outcome Measures in Evaluating Nerve Damage Following Chemotherapy.评价化疗后神经损伤的患者报告结局测量的有效性。
JAMA Netw Open. 2024 Aug 1;7(8):e2424139. doi: 10.1001/jamanetworkopen.2024.24139.
10
Development and psychometric evaluation of the chemotherapy-induced peripheral neuropathy assessment tool.化疗所致周围神经病变评估工具的开发和心理计量学评估。
Cancer Nurs. 2011 Jul-Aug;34(4):E10-20. doi: 10.1097/NCC.0b013e31820251de.

引用本文的文献

1
Peripheral Neuropathy Instruments for Individuals with Cancer: A COSMIN-Based Systematic Review of Measurement Properties.癌症患者外周神经病变检测工具:基于COSMIN的测量属性系统评价
Curr Oncol. 2024 Dec 6;31(12):7828-7851. doi: 10.3390/curroncol31120577.
2
Assessing chemotherapy-induced peripheral neuropathy with patient reported outcome measures: a systematic review of measurement properties and considerations for future use.使用患者报告结局测量评估化疗引起的周围神经病:测量特性的系统评价及未来应用的考虑。
Qual Life Res. 2022 Nov;31(11):3091-3107. doi: 10.1007/s11136-022-03154-7. Epub 2022 May 21.
3
Development and validation of the comprehensive assessment scale for chemotherapy-induced peripheral neuropathy in survivors of cancer.
癌症幸存者化疗诱导周围神经病变综合评估量表的制定与验证。
BMC Cancer. 2019 Sep 10;19(1):904. doi: 10.1186/s12885-019-6113-3.